Targeted Ablation of Canonical Disulfide Bonds Mitigates TCR Mismatching in Engineered T Cells
Su, D.; Liu, G.
Show abstract
T cell receptor-engineered T (TCR-T) cell therapy holds distinct advantages over chimeric antigen receptor (CAR)-T cell therapy in treating solid tumors by exploiting intracellular targets through MHC-mediated antigen presentation. Despite this potential, only one TCR-T therapy has received FDA approval to date. A key challenge lies in chain mispairing between exogenous therapeutic TCR chains and endogenous TCR chains, which compromises membrane localization efficiency and elevates off-target toxicity risks. While multiple engineering strategies have been developed to enhance TCR surface expression, our systematic evaluation using a novel mispairing assessment platform revealed that conventional approaches may paradoxically exacerbate chain mismatching. Through targeted cysteine mutations that disrupt the native interchain disulfide bonds in TCR constant domains, we achieved a substantial reduction in exogenous-endogenous TCR mispairing. Importantly, these structural modifications preserved both high surface expression level and potent tumor-specific cytotoxicity. This innovative engineering approach establishes a critical foundation for clinical-grade manufacturing of TCR-T therapies with enhanced safety profiles.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy 95%
- Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency 94%
- Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma. 94%
Similar papers in this journal
- Naive and in vitro-activated primary mouse CD8+ T cells retain in vivo immune responsiveness after electroporation-based CRISPR/Cas9 genetic engineering 94%
- Gene expression-based identification of antigen-responsive CD8+ T cells on a single-cell level 94%
- Exploration of T-cell immune responses by expression of a dominant-negative SHP1 and SHP2 94%
Similar papers in this journal
- A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer 94%
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma 94%
- The spontaneous neoantigen-specific CD4+ T cell response to a growing tumor is functionally and phenotypically diverse. 94%
Similar papers in this journal
- Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3 94%
- The biochemical function of bivalent aptamer assemblies against B-cell markers CD19 and CD20 94%
- A homodimeric aptamer variant generated from ligand-guided selection activates T-cell receptor cluster of differentiation three complex 92%
Similar papers in this journal
- Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity 94%
- Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2 93%
- Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.